Protocol Ledger

NCT06068465 · Phase III · COMPLETED

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Interventional Phase III clinical trial protocol NCT06068465 sponsored by Tasly Pharmaceutical Group Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-27 Enrollment: 248 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06068465
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)248 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06068465
Protocol FieldVerified Registry Value
NCT IdentifierNCT06068465
Consolidated Lead SponsorTasly Pharmaceutical Group Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment248 participants (ACTUAL)
Registered Start Date2023-09-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI